Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Summary

This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma. Vaccines made from survivin peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy and sargramostim may be a better treatment for malignant glioma.

Timeline

Start

2012-09-05

Primary completion

2014-05-29

Completion

2014-05-29

Drugs

Indications